PL1818059T3 - Środek do zapobiegania lub do leczenia jaskry - Google Patents

Środek do zapobiegania lub do leczenia jaskry

Info

Publication number
PL1818059T3
PL1818059T3 PL05819681T PL05819681T PL1818059T3 PL 1818059 T3 PL1818059 T3 PL 1818059T3 PL 05819681 T PL05819681 T PL 05819681T PL 05819681 T PL05819681 T PL 05819681T PL 1818059 T3 PL1818059 T3 PL 1818059T3
Authority
PL
Poland
Prior art keywords
glaucoma
therapeutic agent
preventive
salt
preventing
Prior art date
Application number
PL05819681T
Other languages
English (en)
Inventor
Makoto Kanebako
Masatoshi Takahashi
Ken Mizuno
Shin Sugimoto
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of PL1818059T3 publication Critical patent/PL1818059T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL05819681T 2004-12-23 2005-12-22 Środek do zapobiegania lub do leczenia jaskry PL1818059T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63811804P 2004-12-23 2004-12-23
PCT/JP2005/023570 WO2006068208A1 (ja) 2004-12-23 2005-12-22 緑内障予防又は治療剤
EP05819681A EP1818059B1 (en) 2004-12-23 2005-12-22 Preventive or therapeutic agent for glaucoma

Publications (1)

Publication Number Publication Date
PL1818059T3 true PL1818059T3 (pl) 2009-05-29

Family

ID=36601805

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05819681T PL1818059T3 (pl) 2004-12-23 2005-12-22 Środek do zapobiegania lub do leczenia jaskry

Country Status (23)

Country Link
EP (1) EP1818059B1 (pl)
JP (1) JP4099201B2 (pl)
KR (1) KR101286813B1 (pl)
CN (1) CN101087613B (pl)
AT (1) ATE415972T1 (pl)
AU (1) AU2005320085B2 (pl)
BR (1) BRPI0519007A2 (pl)
CA (1) CA2585372A1 (pl)
CY (1) CY1108651T1 (pl)
DE (1) DE602005011476D1 (pl)
DK (1) DK1818059T3 (pl)
EA (1) EA011085B1 (pl)
ES (1) ES2317338T3 (pl)
MX (1) MX2007007614A (pl)
MY (1) MY138811A (pl)
NO (1) NO20072187L (pl)
NZ (1) NZ555137A (pl)
PL (1) PL1818059T3 (pl)
PT (1) PT1818059E (pl)
SI (1) SI1818059T1 (pl)
TW (1) TWI367098B (pl)
WO (1) WO2006068208A1 (pl)
ZA (1) ZA200704874B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090079689A1 (en) * 2005-07-14 2009-03-26 Akio Miyata Display Device And Electric Apparatus Using The Same
JPWO2010010715A1 (ja) 2008-07-25 2012-01-05 旭化成ファーマ株式会社 スルホンアミド化合物を含有する安定な水溶液組成物
TW201906614A (zh) * 2011-02-04 2019-02-16 日商興和股份有限公司 青光眼或高眼壓症之預防或治療用之點眼藥
EA026904B1 (ru) * 2012-11-23 2017-05-31 Игорь Михайлович Юхт Способ количественного определения полигексаметиленбигуанидина (пгмб) гидрохлорида в составах для приготовления жидких лекарственных средств для лечения заболеваний глаз и носа (2 варианта)
JP5557408B1 (ja) * 2013-04-24 2014-07-23 国立大学法人九州大学 眼底疾患治療剤
DK3199160T3 (da) * 2014-09-25 2020-04-20 Kowa Co Vandig sammensætning
JP6236167B2 (ja) * 2014-09-25 2017-11-22 興和株式会社 医薬品
SG11201704737SA (en) 2014-12-12 2017-07-28 Kowa Co Novel aqueous composition
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法
KR20160108121A (ko) 2015-03-06 2016-09-19 코와 가부시키가이샤 수성 조성물
JP2018118905A (ja) * 2015-04-27 2018-08-02 恵 本庄 白内障術後合併症の予防治療剤
CN106310285A (zh) * 2015-06-15 2017-01-11 江苏吉贝尔药业股份有限公司 一种新的盐酸利舒地尔滴眼液及其制备方法
JP6886322B2 (ja) * 2016-03-25 2021-06-16 興和株式会社 眼科用組成物
CN107164328A (zh) * 2017-06-30 2017-09-15 太仓卡斯特姆新材料有限公司 一种高稳定性mcf‑7乳腺癌细胞的复苏方法
EP3730138B1 (en) 2017-12-21 2024-02-14 Santen Pharmaceutical Co., Ltd. Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
JP2020193174A (ja) * 2019-05-29 2020-12-03 興和株式会社 水性組成物
CA3207859A1 (en) 2021-01-11 2022-07-14 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9401108D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
DE19512639A1 (de) * 1995-04-05 1996-10-10 Merck Patent Gmbh Benzonitrile und -fluoride
JP3719609B2 (ja) * 1995-12-21 2005-11-24 アルコン ラボラトリーズ，インコーポレイテッド 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用
JPH10310576A (ja) * 1997-03-10 1998-11-24 Hiroyoshi Hidaka イソキノリンスルフォンアミド誘導体及びこれを有効成分とする医薬
WO1999054306A1 (en) * 1997-03-10 1999-10-28 Hiroyoshi Hidaka Isoquinolinesulfonamide derivatives and drugs containing the same as the active ingredient
CA2288910C (en) * 1997-04-25 2003-06-24 Pfizer Inc. Pyrazolopyrimidinones for sexual dysfunction
FR2777189B1 (fr) 1998-04-09 2001-04-06 Chauvin Lab Sa Composition ophtalmique comprenant un beta-bloquant
JP4212149B2 (ja) * 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
KR100616466B1 (ko) 1998-08-17 2006-08-29 센주 세이야꾸 가부시키가이샤 녹내장 예방/치료제
EP1514867A3 (en) * 1998-10-22 2005-03-23 NeuroSearch A/S Substituted phenyl derivatives, their preparation and use

Also Published As

Publication number Publication date
HK1113312A1 (zh) 2008-10-03
ZA200704874B (en) 2008-08-27
TW200628160A (en) 2006-08-16
DK1818059T3 (da) 2009-03-16
EP1818059A4 (en) 2007-12-26
CN101087613A (zh) 2007-12-12
EP1818059B1 (en) 2008-12-03
MX2007007614A (es) 2007-08-15
EA011085B1 (ru) 2008-12-30
SI1818059T1 (sl) 2009-04-30
CY1108651T1 (el) 2014-04-09
ES2317338T3 (es) 2009-04-16
ATE415972T1 (de) 2008-12-15
PT1818059E (pt) 2008-12-31
NZ555137A (en) 2009-10-30
AU2005320085B2 (en) 2010-07-29
CA2585372A1 (en) 2006-06-29
WO2006068208A1 (ja) 2006-06-29
CN101087613B (zh) 2010-08-18
TWI367098B (en) 2012-07-01
AU2005320085A1 (en) 2006-06-29
JPWO2006068208A1 (ja) 2008-06-12
MY138811A (en) 2009-07-31
NO20072187L (no) 2007-07-13
EP1818059A1 (en) 2007-08-15
BRPI0519007A2 (pt) 2008-12-23
DE602005011476D1 (de) 2009-01-15
EA200701134A1 (ru) 2007-10-26
KR20070090897A (ko) 2007-09-06
KR101286813B1 (ko) 2013-07-17
JP4099201B2 (ja) 2008-06-11

Similar Documents

Publication Publication Date Title
NO20072187L (no) Preventivt eller terapeutisk middel for glaucom
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2006066103A3 (en) Ophthalmic implant for treatment of glaucoma
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2003005941A3 (de) Insert zur behandlung des trockenen auges
WO2007126364A8 (en) Use of antisecretory factors for treating intraocular hypertension
WO2002098350A3 (en) Pyranoindazoles and their use for the treatment of glaucoma
WO2004069181A3 (en) Composition for the treatment of intraocular pressure
WO2007076367A3 (en) Rnai-mediated inhibition of rho kinase for treatment of ocular hypertension / glaucoma
WO2006068829A9 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (lox) and lox-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2007127711A3 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
ZA200607988B (en) Statins for the treatment of ocular hypertension and glaucoma
WO2004019874A3 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
EP1482922A4 (en) AGENTS FOR CORNEAL OR INTRASTROMAL ADMINISTRATION FOR TREATING OR PREVENTING OCULAR DISORDERS
WO2005021026A3 (en) Methods for treating or ameliorating ghrelin-associated diseases and disorders
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
TW200806284A (en) Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
WO2003101379A3 (en) Pyranoindazoles and their use for the treatment of glaucoma
WO2002060339A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004087051A3 (en) Ophthalmic compositions for treating ocular hypertension
TW200600099A (en) Therapeutic or preventive agent for eye disease
WO2003082257A3 (en) Method for treating ocular hypertension and glaucoma